[Quantitative whole-body bone scintigraphy. II. Pharmacokinetics of osteotropic radiopharmaceuticals (author's transl)].
85Sr, 99mTc-Sn-pyrophosphate and 99mTc-Sn-methylene-diphosphonate, the most important agents for skeletal imaging, are compared with each other by calculation of the plasma clearance and the urinary excretion and by a series of quantitative whole-body scans. 85Sr the distribution volume in equilibrium is the largest, shifting of activity is demonstrable for several days after injection. 99mTc-Sn-MDP is excreted most quickly, equilibrium is reached early. There is no significant difference in skeletal uptake between the phosphate complexes. The distribution however is different: 85Sr is localized to a greater extent in the extremities, the phosphate complexes more in the trunk, 99mTc-Sn-MDP and 85Sr nearer the joints than 99mTc-Sn-pyrophosphate.
D001842:Bone and Bones / Q000000981:diagnostic imaging*; D004164:Diphosphonates / Q000097:blood / Q000652:urine; D006801:Humans; D011122:Polyphosphates; D011877:Radionuclide Imaging; D013326:Strontium Radioisotopes / Q000097:blood / Q000652:urine; D013667:Technetium / Q000097:blood / Q000652:urine; D013669:Technetium Tc 99m Medronate; D016698:Technetium Tc 99m Pyrophosphate; D014003:Tin Polyphosphates / Q000097:blood / Q000652:urine
D004164:Diphosphonates; D011122:Polyphosphates; D013326:Strontium Radioisotopes; D014003:Tin Polyphosphates; C017742:technetium Tc 99m stannous pyrophosphate; D016698:Technetium Tc 99m Pyrophosphate; C023568:technetium Tc 99m (Sn)methylenediphosphonate; D013667:Technetium; D013669:Technetium Tc 99m Medronate
Die quantitative Ganzkörper-Skelettszintigraphie. II. Aussage für die Kinetik osteotroper Radiopharmaka.